Evidence map›Paper›PMID 40873400›Full record

ArticleActa biochimica et biophysica Sinica2025

Exploring DNA topoisomerase II alpha in adrenocortical carcinoma through multi-omics analysis: a potential biomarker and therapeutic target.

Jianming Lu, Pei Deng, Zhenjie Wu, Yuxiang Liang, Yangjia Zhuo, Yongding Wu, Yingke Liang, Jianheng Ye, Wenjie Xie, Zhouda Cai and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jianming LuDepartment of Andrology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China.
Pei DengDepartment of Urology, Minimally Invasive Surgery Center, the First Affiliated Hospital of Guangzhou Medical University, Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, Guangzhou 510230, China.
Zhenjie WuDepartment of Urology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Yuxiang LiangDepartment of Urology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Yangjia ZhuoDepartment of Urology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Yongding WuDepartment of Urology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Yingke LiangDepartment of Urology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Jianheng YeDepartment of Urology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Wenjie XieDepartment of Urology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Zhouda CaiDepartment of Andrology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China.
Chao CaiDepartment of Urology, Minimally Invasive Surgery Center, the First Affiliated Hospital of Guangzhou Medical University, Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, Guangzhou 510230, China.
Jiahong ChenDepartment of Urology, Huizhou Municipal Central Hospital, Huizhou 516008, China.
Le ZhangInstitute for Integrative Genome Biology, University of California, Riverside, California 92507, USA.
Junhong DengDepartment of Andrology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China.
Weide ZhongDepartment of Urology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Jiaojiao TangDepartment of Cardiology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
Zhaodong HanDepartment of Urology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenocortical carcinoma (ACC) is a rare but aggressive cancer. Recent studies identified DNA Topoisomerase II Alpha (TOP2A) as a potential biomarker for ACC, which can provide new avenues for targeted therapy and improve clinical outcomes. This study aims to elucidate the role of TOP2A in ACC by exploring its prognostic value and identifying inhibitors for ACC therapy. Utilizing RNA sequencing data, mutation data, and clinical information from The Cancer Genome Atlas (TCGA-ACC) and additional datasets from the Gene Expression Omnibus (GEO), differential expression and prognostic analyses are conducted to assess the significance of TOP2A in ACC. Immunohistochemistry and cell assays, including cell viability, colony formation, and transwell assays, are conducted to validate the oncogenic effects of TOP2A. The "IOBR" R package is used to examine the relationship between TOP2A expression and CD8

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaBiomarkers, TumorDNA Topoisomerases, Type IIPoly-ADP-Ribose Binding ProteinsAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMultiomicsPrognosisTopoisomerase II InhibitorsBiomarkers, TumorDNA Topoisomerases, Type IIPoly-ADP-Ribose Binding ProteinsTOP2A protein, humanTopoisomerase II Inhibitorsadrenocortical carcinomaimmunotherapy responseprognosistherapeutic inhibitorsTOP2A

Identifiers

PMID40873400
PMCPMC13059743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.